Alfred L. Garfall

Alfred L. Garfall uniquely bridges CAR-T cell therapy and bispecific antibody development for multiple myeloma. His 2015 NEJM co-first authorship demonstrating CD19 CAR-T responses in myeloma established proof-of-concept for cellular therapy within Carl June's Penn CAR-T program. Building on this, he served as key investigator for MajesTEC-1, earning second-author position on both Lancet 2021 and NEJM 2022 publications supporting teclistamab FDA approval. As Director of Autologous HCT and Myeloma Section Chief at Penn, he leads clinical trials spanning both modalities. His LLS-funded research now explores limited-duration bispecific dosing to improve quality of life.

Alfred L. Garfall博士独特地连接了多发性骨髓瘤的CAR-T细胞疗法和双特异性抗体开发。他2015年NEJM共同第一作者论文展示了CD19 CAR-T在骨髓瘤中的反应，在Carl June的宾大CAR-T项目中确立了细胞疗法的概念验证。在此基础上，他担任MajesTEC-1的关键研究者，在支持teclistamab FDA批准的Lancet 2021和NEJM 2022论文中均获得第二作者地位。作为宾大自体HCT主任和骨髓瘤分部主任，他领导涵盖两种模式的临床试验。他目前由LLS资助的研究探索限时双特异性抗体给药以改善生活质量。